baber/WOPTO huggingface dataset:
Patent JP-3162071-B2 (JP)
IPC: A61K31/445
Filed: 1992-02-18
Granted: 2001-04-25
Abstract: Invented are methods of inhibiting the production of cytokines, particularly inhibiting the production of interleukin-1 and inhibiting the production of tumor necrosis factor in a mammal in need thereof which comprises administering to such mammal an effective amount of an azaspirane derivative.
Patent JP-4251407-B2 (JP)
IPC: C12N15/40
Filed: 1993-11-26
Granted: 2009-04-08
Abstract: The present invention relates to new HCV viruses characterized by new 5'UTR or NS5 sequences. The present invention relates to methods for dectection of said viruses, nucleic acid and polypeptides sequences encoding by said viruses and their use in diagnostic kits.
Patent JP-3304981-B2 (JP)
IPC: A61C15/04
Filed: 1995-10-10
Granted: 2002-07-22
Abstract: PCT No. PCT/EP95/03978 Sec. 371 Date Apr. 11, 1997 Sec. 102(e) Date Apr. 11, 1997 PCT Filed Oct. 10, 1995 PCT Pub. No. WO96/11599 PCT Pub. Date Apr. 25, 1996A dispenser for a cleaning and dental-care formulation which is present in solid form as a sheet (1) and is provided in conjunction with a toothbrush (10) for oral and dental hygiene is characterized in that the dispenser and the toothbrush (10) together are designed as a functional unit (20).
Patent JP-3355578-B2 (JP)
IPC: B01D29/25
Filed: 1993-04-08
Granted: 2002-12-09
Abstract: PCT No. PCT/FI93/00151 Sec. 371 Date Oct. 13, 1994 Sec. 102(e) Date Oct. 13, 1994 PCT Filed Apr. 8, 1993 PCT Pub. No. WO93/22494 PCT Pub. Date Nov. 11, 1993An apparatus for screening and thickening cellulose pulp keeps cleaner than conventional apparatus. Pulse members in accordance with the prior art are constructed so that when the capacity of the screening apparatus is increased, for example by using greater pressure differences or the cleanliness of the accept is increased by decreasing the size of the perforations or slots, a situation is created in which the screen cylinder tends to clog. The pulse member of the present screening apparatus subjects the screen cylinder or screen surface to a pulse cleaning action so that there is a minimal possibility to allow the pressure effect to "escape" past the area being cleaned. The higher the consistency of the fiber matting is or the worse the screen surface is clogged, the stronger the pulse cleaning of the screen surface.
Patent JP-3899440-B2 (JP)
IPC: C07H19/00
Filed: 1995-01-30
Granted: 2007-03-28
Abstract: A method for the treatment of a host, and in particular, a human, infected with HBV or EBV is provided that includes administering an HBV- or EBV- treatment amount of an L-nucleoside of formula (I) <CHEM> wherein R is a purine or pyrimidine base. In one preferred embodiment, the active compound is 2'-fluoro-5-methyl- beta -L-arabinofuranosyluridine (also referred to as L-FMAU) This compound is a potent antiviral agent against HBV and EBV and exhibits low cytotoxicity. Other specific examples of active compounds include N1-(2'-deoxy-2'-fluoro- beta -L-arabinofuranosyl)-5-ethyluracil, N1-(2'-deoxy-2'-fluoro- beta -L-arabinofuranosyl)-5-iodocytosine), and N1-(2'-deoxy-2'-fluoro- beta -L-arabinofuranosyl)-5-iodouracil. <IMAGE>
Patent JP-3980055-B2 (JP)
IPC: C12N15/00
Filed: 1996-02-16
Granted: 2007-09-19
Abstract: The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360-386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and of select tumor-derived p53 mutants. Pharmaceutical compositions of the compounds of the invention and methods of using these compositions therapeutically are also provided.
Patent JP-3796267-B2 (JP)
IPC: F24F9/00
Filed: 1997-12-24
Granted: 2006-07-12
Abstract: A device for dynamically separating two zones by a bufer zone and two clean air curtains. When transferring objects at high speed between two zones, a buffer zone which is connected to the two zones, forms a dynamic lock in order to separate them. a dynamic confinement system placed between each pair of adjacent communication zones forms an air curtain including two or three clean air jets. The buffer zone includes a blower ceiling and an intake grill facing it.
Patent JP-3336317-B2 (JP)
IPC: A61F2/28
Filed: 1995-05-17
Granted: 2002-10-21
Abstract: An expandable, porous fabric implant for insertion into the interior of a reamed out disc which is packed with material to stabilize the spinal segment. The fabric pores allows for tissue ingrowth through the implant.
Patent JP-3009229-B2 (JP)
IPC: C07C47/02
Filed: 1995-06-23
Granted: 2000-02-14
Abstract: This invention relates to membrane separation of organic solubilized rhodium-organophosphite complex catalyst and free organophosphite ligand from a homogeneous non-aqueous hydroformylation reaction mixture, said mixture also containing, in addition to said catalyst and free ligand, aldehyde product and an organic solvent.
Patent JP-3335181-B2 (JP)
IPC: B67C3/32
Filed: 1998-03-18
Granted: 2002-10-15
Abstract: Disclosed is a method for filling barrels (4), specially kegs, with liquids, wherein at least one gas is dissolved. The barrel (4) is pre-stressed using a gas before the liquid is filled. Liquid is then fed into the barrel (4) by means of a filling valve (2) pertaining to a filling station (1) and connected to a feed line (3, 8). During filling, the pre-stress gas contained in the barrel (4) is evacuated. So as not to impair the product, the pre-stress gas in the barrel (4) is pre-stressed at only a partial pressure which corresponds approximately to the saturation pressure of the CO2 or N2 which is dissolved in the filled liquid. Said partial pressure is lower than the maximum product pressure occurring in the feed line (8) prior to the filling valve (2).
Patent ES-2465997-B2 (ES)
Title: Equipo para ensayo petrofísico
Inventor: MARTINEZ DIAZ CARLOS
IPC: G01N23/02
Filed: 2012-12-07
Granted: 2015-05-20
Abstract: Equipo para ensayo petrofísico que tiene una celda que tiene: un cuerpo (1) que comprende una cavidad (1.a) configurada para alojar una muestra a ser analizada; dos pistones de entradas/salidas (1.d) que comprende una pluralidad de conductos de entrada (101, 102, 103, 104) y una pluralidad de conductos de salida (101, 102,103, 104) configurados para permitir dos entradas/salidas de fluidos; donde el cuerpo (1) y los pistones de entradas/salidas (1.d) están unidos para conformar una celda estanca.
Patent ES-2558053-B2 (ES)
Title: Colector de calor para la generación de energía térmica solar
Inventor: KAGEYAMA Taketomo
IPC: F24S10/80
Filed: 2013-05-17
Granted: 2016-07-06
Abstract: Colector de calor para la generación de energía térmica solar.#Se proporciona un colector de calor (1) para la generación de energía térmica solar que suprime la oxidación utilizando un cuerpo sinterizado de cerámica de carburo de silicio como cuerpo base (10). El colector de calor incluye el cuerpo base hecho de un cuerpo sinterizado de cerámica de carburo de silicio en el cual están formados canales (células (15)) para hacer pasar un medio de calor, una primera capa de vidrio (21) de vidrio de silicato que recubre por lo menos una parte de superficies del cuerpo base y que contiene un componente de metal alcalino y/o un componente de metal alcalinotérreo, y una segunda capa de vidrio (22) de vidrio de silicato que recubre la primera capa de vidrio y que tiene una suma de contenidos de un componente de metal alcalino y de un componente de metal alcalinotérreo que es inferior a la suma de contenidos del componente de metal alcalino y del componente de metal alcalinotérreo en la primera capa de vidrio.
Patent AU-2001250329-B2 (AU)
Title: Hybrid ARQ method with signal constellation rearrangement
Inventor: WENGERTER CHRISTIAN
IPC: H04L1/18
Filed: 2001-02-21
Granted: 2003-10-30
Abstract: A hybrid ARQ retransmission method involves encoding data packets with a forward error correction (FEC) technique prior to transmission. The data packets are retransmitted based on an automatic repeat request (ARQ) and subsequently soft-combined with previously received erroneous data packets either on a symbol-by-symbol or a bit-by-bit basis. The symbols of the erroneous data packets are modulated by employing a first signal constellation. The symbols of the re-transmitted data packets are modulated by employing at least a second signal constellation. Each symbol bit has a mean bit reliability defined by the individual bit reliabilities over all symbols of the predetermined signal constellation. The first constellation and the at least second signal constellation are selected such that the combined mean bit reliabilities for the respective bits of all transmissions are averaged out.
Patent AU-2001254568-B2 (AU)
Title: Adjustable water-fillable exercise weights
Inventor: BARBER STEPHEN
IPC: A63B21/072
Filed: 2001-04-26
Granted: 2007-02-01
Abstract: A readily portable dumbell or barbell for exercising and weight training is provided in which weight units on an elongated handle comprise front and rear end plates interconnected by a collapsible/expandible fluid receptacle in the form of a resilient bellows. The weight unit is lengthened and expanded when fluid is added and is shortened and decreased in volume when fluid is removed. Calibration means are provided for visually indicating the weight of the unit corresponding to the longitudinal spacing between the front and end plates of the unit. In a preferred embodiment, a visually readable measurement of weight is provided by means for a graduated bar insert which extends slidably within the hollow handle of the dumbell or barbell and moves therealong with expansion or contraction of the water-filled bellows.
Patent AU-2001257236-B2 (AU)
Title: Joint repair using mesenchymal stem cells
Inventor: MOSELEY ANNEMARIE
IPC: A61K35/12
Filed: 2001-04-24
Granted: 2006-03-09
Abstract: A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue.
Patent AU-2001283005-B2 (AU)
Title: Iso-truss structure
Inventor: FRANCOM LARRY R
IPC: A45F3/04
Filed: 2001-07-27
Granted: 2007-03-22
Abstract: An iso-truss structure ( 10 ) includes at least two helical components ( 30, 32 ) and at least one reverse helical component ( 34 ) attached thereto with opposing angular orientations. Each helical and reverse helical component preferably includes at least four elongate, straight segments ( 22 ) rigidly connected end to end in a helical configuration forming a single, substantially complete rotation about a common axis ( 14 ) forming a first square cross section. The structure may further include at least two rotated helical components ( 80, 92 ) and at least one rotated reverse helical component ( 98 ) which are rotated with respect to the helical and reverse helical components forming a second square cross section, rotated with respect to the first. The structure may be straight, curved, flexible, or form angles.
Patent AU-2002216763-B2 (AU)
Title: Alteration of cell membrane
Inventor: SHIRWAN HAVAL
IPC: C12N5/08
Filed: 2001-07-02
Granted: 2007-03-01
Abstract: Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis.
Patent AU-2002233209-B2 (AU)
Title: Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
Inventor: FRIDERICHS ELMAR
IPC: A61K31/13
Filed: 2001-11-28
Granted: 2006-05-11
Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula I: It has been surprisingly discovered that the pharmaceutical composition of the present invention is effective for the treatment of increased urge to urinate or urinary incontinence. Also disclosed are methods of treatment using the pharmaceutical compositions.
Patent AU-2002339430-B2 (AU)
Title: Method and device for active radial control of wheel pairs or wheel sets on vehicles
Inventor: AUER WOLFGANG
IPC: B61F5/38
Filed: 2002-07-29
Granted: 2008-07-03
Abstract: The invention relates to a method for active radial control of the wheels (11, 53, 103, 108, 115) of at last one wheel unit (8, 9, 10, 51, 52) on a chassis, in particular a bogie on a tracked vehicle, whereby control movements are applied to the wheel unit (8, 9, 10, 51, 52) and an integrated regulation with control movements in at least two non-identical frequency ranges are carried out. First control movements in a first frequency range and second control movements in a second frequency range, different form the first frequency range are superimposed and applied to the wheel unit (8, 9, 10, 51, 52). The invention also relates to a device for carrying out the method.
Patent AU-2002345669-B2 (AU)
Title: Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells
Inventor: AL-MAHMOOD SALMAN
IPC: A61P9/10
Filed: 2002-06-14
Granted: 2006-02-02
Abstract: Angiogenesis-modifying composition (A) containing at least one of a nucleic acid (I) from the gene encoding IRS-1 (insulin receptor substrate-1), or its complement or fragments, or a molecule (II) that inhibits expression of the nucleic acid, is new. ACTIVITY : Ophthalmological; Antiarthritic; Antirheumatic; Antiinflammatory; Gynecological; Antipsoriatic; Cytostatic; Vasotropic; Hypotensive; Vulnerary; Antianginal; Cardiant; Osteopathic. Corneal wounds were made in rats as described in Invest. Ophthalmol. Vis. Sci., 39 (1998) 18, then the animals given a subconjunctival injection of a composition containing 60 MicroM of the oligonucleotide (3), antisense to the IRS-1 gene 5'-TATCCGGAGGGCTCGCCATGCTGCT (3) in buffered saline, every day from days 4 to 9. The animals were killed on day 10 and the degree of neovascularization determined by staining with fluorescein-dextran, photography under a fluorescent microscope and then the ratio of neovascularized surface to total corneal surface was calculated. This ratio was 0.6157 (n = 15) for treated animals, compared with 0.9552 (n = 9) for those injected with saline only and 0.9170 (n = 9) for untreated animals, indicating a statistically significant reduction in neovascularization caused by (3). Similar results were obtained by topical application of an ointment containing 200 MicroM (3). MECHANISM OF ACTION : Antisense gene therapy.
Patent AU-2003210928-B2 (AU)
Title: Electrochromic display device
Inventor: FLICK DERRICK W
IPC: G02F1/155
Filed: 2003-02-07
Granted: 2008-09-04
Abstract: The invention is a display device comprising a solid top transparent, charge conducting material, positioned below the transparent solid material is an active layer comprising an electrochromic material and an electrolyte, and positioned below the active layer is a working electrode and a counter-electrode arranged to be isolated from one another, wherein the distance between the working and the counter electrode is greater than two times the thickness of the active layer between the electrode and the conductive material.
Patent AU-2003230902-B2 (AU)
Title: Foam security substrate
Inventor: JENNEN JAY M
IPC: B29L7/00
Filed: 2003-04-10
Granted: 2007-06-21
Abstract: The present invention is directed an oriented, foamed article having an ink-receptive surface, and a method of making the article. The invention provides a printable substrate comprising at least one high melt-strength, oriented polypropylene foam layer having an ink-receptive surface. The high melt-strength polypropylene having a melt strength of of 25 to 60 cN at 190° C. The ink-receptive surface may comprise and oxidizing treatment, such as corona or flame-treatment of the foam surface, or may comprise an ink-receptive coating, such as a primer coating, on the foam surface. The oriented foam article is particularly useful in the preparation of printed security documents such as currency, stock and bond certificates, birth and death certificates, land titles and abstracts and the like.
Patent AU-2004224156-B2 (AU)
Title: Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
Inventor: CLOZEL MARTINE
IPC: C07D217/02
Filed: 2004-03-23
Granted: 2010-08-12
Abstract: The invention relates to novel acetamide derivatives of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.
Patent AU-2005262637-B2 (AU)
Title: Fire resistant PV shingle assembly
Inventor: ALMY CHARLES
IPC: E04B1/62
Filed: 2005-05-27
Granted: 2008-10-16
Abstract: A shingle system, mountable to a support surface, includes overlapping shingle assemblies. Each shingle assembly comprises a support bracket, having upper and lower ends, secured to a shingle body. The upper end has an upper support portion, extending away from the shingle body, and an upper support-surface-engaging part, engageable with a support surface so that the upper edge of the shingle body is positionable at a first distance from the support surface to create a first gap therebetween. The lower end has a lower support portion extending away from the lower surface. The support brackets create: (1) a second gap between shingle bodies of the first and second shingle assemblies, and (2) an open region beneath the first shingle assembly fluidly coupling the first and second gaps.
Patent AU-2005334923-B2 (AU)
Title: Composition for preventing harmful organisms
Inventor: NOBUYUKI KAWAHARA
IPC: A01N37/22
Filed: 2005-07-27
Granted: 2011-10-20
Abstract: There is a pest that cannot be controlled or is difficult to be controlled with the use of a single agent of a compound represented by the general formula (1) according to the invention, an insecticide, a miticide or a bacteriocide. Accordingly, an object of the invention is to provide a pest control composition for efficiently controlling such a pest. That is, the invention is directed to a pest control composition, characterized by comprising as active ingredients, the compound represented by the general formula (1) and another insecticide, miticide or bacteriocide. (1) (In the formula, A, A, A and A independently represent a carbon atom, a nitrogen atom or an oxidized nitrogen atom; G and G independently represent an oxygen atom or a sulfur atom; R and R independently represent a hydrogen atom or a C to C alkyl group; Xs may be the same or different and represent a hydrogen atom, a halogen atom or a trifluoromethyl group; Q represents a substituent such as a phenyl group or a heterocyclic group; and Q represents a substituent such as a phenyl group or a heterocyclic group.)
Patent AU-2006219717-B2 (AU)
Title: Pharmaceutical composition
Inventor: ELVIN STEPHEN J
IPC: A61K39/07
Filed: 2006-03-02
Granted: 2009-05-21
Abstract: A microparticle composition comprising a biodegradable polymer, an immunogenic single-stranded ribonucleic acid (ss-RNA) material, a biologically active macromolecule and a stabilising agent wherein the outer surface of the resulting microparticle is free from adsorbed molecules is described. The composition is effective in providing an immune response in dendritic cells, in particular by stimulating increased production of IFN-alpha. Methods of production and uses, in medicine, of pharmaceutical compositions derived from the microparticles are also claimed and described.
Patent AU-2006227377-B2 (AU)
Title: Framework-shuffling of antibodies
Inventor: DALL ACQUA WILLIAM
IPC: C12N15/87
Filed: 2006-03-17
Granted: 2013-01-31
Abstract: The present invention relates to methods of reengineering or reshaping antibodies to reduce the immunogenicity of the antibodies, while maintaining the immunospecificity of the antibodies for an antigen. In particular, the present invention provides methods of producing antibodies immunospecific for an antigen by synthesizing a combinatorial library comprising complementarity determining regions (CDRs) from a donor antibody fused in frame to framework regions from a sub-bank of framework regions. The invention also provides method of producing improved humanized antibodies. The present invention also provides antibodies produced by the methods of the invention.
Patent AU-2006271163-B2 (AU)
Title: Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
Inventor: NACCARI GIANCARLO
IPC: C07C229/64
Filed: 2006-07-24
Granted: 2012-03-15
Abstract: Therefore the present invention relates specifically to the compounds of general formula (I), in which R and R, which may be identical or different, are selected from the group comprising H -CH, a linear or branched alkyl group having from 1 to 6 carbon atoms, or together form an aromatic or aliphatic ring with 5 or 6 atoms; R is selected from -CO-CH, -NHOH, -OH, -OR in which R is a linear or branched alkyl group having from 1 to 6 carbon atoms; R is selected from H, a linear or branched alkyl group having from 1 to 6 carbon atoms, phenyl, benzyl, -CF or -CFCF, vinyl or allyl; R, R, R are hydrogen atoms; or R and R, R and R, or R and R together form a ring, fused to the benzene, aromatic or aliphatic ring with 5 or 6 atoms comprising from 1 to 2 heteroatoms selected independently from the group comprising N, O. and use thereof in the medical field.
Patent AU-2006304874-B2 (AU)
Title: Pyrimidinones as casein kinase II (CK2) modulators
Inventor: KENNEDY ABIGAIL R
IPC: A61P35/00
Filed: 2006-10-23
Granted: 2013-03-07
Abstract: A compound having Formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R
Patent AU-2007217119-B2 (AU)
Title: Enzyme detection
Inventor: DAVIS PAUL JAMES
IPC: B01L3/00
Filed: 2007-02-23
Granted: 2012-04-19
Abstract: An enzyme detection product (1) for detecting the presence of an enzyme in a sample. The product (1) comprises: a reaction zone (16) for receiving the sample; a visualisation zone (10) for presenting a signal in response to the detection of the activity of the enzyme; and a membrane (11). The membrane (11) is interposable between the reaction zone (16) and the visualisation zone (10) and prevents passage from the reaction zone (16) to the visualisation zone (10) the components having a size greater than a threshold size. The reaction zone (16) comprises a reactant capable of reacting with the enzyme in order to generate a reaction product having a size less than a threshold size.